STOCK TITAN

Agile Therapeutics Inc - AGRX STOCK NEWS

Welcome to our dedicated news page for Agile Therapeutics (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on Agile Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agile Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agile Therapeutics's position in the market.

Rhea-AI Summary
Agile Therapeutics, Inc. (AGRX) announced the immediate exercise of outstanding warrants to purchase 3,892,572 shares of common stock at a reduced price of $1.25 per share, expecting gross proceeds of approximately $4.8 million. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics, Inc. (AGRX) has been granted an extension by Nasdaq to regain compliance with the stockholders' equity requirement until March 25, 2024. The company expects a significant increase in net revenue for full year 2023, ranging from $20 to $21 million, representing an 84% to 93% growth compared to 2022. Additionally, GAAP operating expenses for full year 2023 are anticipated to decrease by 47% to 44% compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics, Inc. commends the Biden-Harris Administration for their continued commitment to reproductive health, including increasing access to no-cost contraception. The new guidance released by the Departments of Labor, Health and Human Services, and the Treasury outlines a new pathway for plans and issuers to cover a broader range of FDA-approved contraceptive drugs and certain devices at no cost. This comes after President Biden's Executive Order in June 2023, directing the Secretaries to ensure comprehensive contraceptive care coverage without cost-sharing for enrollees, participants, and beneficiaries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) is commending House Committee on Oversight and Accountability Ranking Member Jamie Raskin for a new report on contraception coverage gaps, following several months of activity by the Biden Administration and lawmakers to strengthen access to contraception. The report could potentially eliminate financial barriers for contraceptive products like Twirla® for 49 million women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
none
-
Rhea-AI Summary
Agile Therapeutics, Inc. (AGRX) reported a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ, its birth control patch. The company also aims to achieve at least $25 million in full-year 2023 revenue and be cash flow positive from operations in the first quarter of 2024. Agile's Chair and CEO, Al Altomari, highlighted the company's achievements in net revenue, Twirla demand, factory sales, and gross margin. The company expects further growth from expanding its customer bases, boosting non-retail customer networks, and advancing Twirla through telemedicine platforms. Maxim Group recently upgraded its investment rating for Agile to buy from hold, setting a 12-month price target of $5.00, representing a 150% upside potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
earnings
-
Rhea-AI Summary
Agile Therapeutics, Inc. (Nasdaq: AGRX) reports a 21% increase in net revenue to $6.7 million in Q3 2023, with a gross margin growth to 63%. The company reaffirms its expected full-year 2023 net revenue of at least $25 million and anticipates positive cash flow from operations in Q1 2024. Management will host a conference call on November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
earnings
Rhea-AI Summary
Agile Therapeutics, Inc. will report its third quarter 2023 financial results on November 9, 2023. A live conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences earnings
-
Rhea-AI Summary
Agile Therapeutics grants inducement award to new CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary
Maxim Group upgrades Agile Therapeutics Inc. (NASDAQ:AGRX) to a 'buy' rating with a one-year price target of $5, nearly 180% increase from current level. Twirla sales accelerating significantly in 2Q23, expected to continue. Nurx partnership expands retail channel presence. 2023 revenue estimate increased to $25.3M, 2024 estimate to $42.9M. Gross margins expected to expand to 70% in 4Q23. Financing overhang but breakeven could come by 1H24. Upgrade to Buy, establishing a 12-month price target of $5.00.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
none
Rhea-AI Summary
Agile Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
conferences
Agile Therapeutics Inc

Nasdaq:AGRX

AGRX Rankings

AGRX Stock Data

2.34M
2.51M
1.14%
10.13%
6.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Princeton

About AGRX

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.